Topical administration of the TLR7 agonist imiquimod elicits a potent type I interferon response and has efficacy for the treatment of genital warts, VIN and CIN, presumably by enhancing and targeting spontaneous immunity and counteracting a suppressive microenvironment [17], [56], [57]. Here, TLR7 is linked to anogenital human papillomavirus infection.